.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,750,029

« Back to Dashboard

Claims for Patent: 7,750,029

Title:Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Abstract: (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or its salt shows a potent bladder relaxation effect in "isolated rat bladder smooth muscle relaxation test", dose-dependently lowers the contraction frequency of rhythmic bladder contractions in "rat rhythmic bladder contraction measurement test" and, moreover, prolongs the urination intervals in "urination functions measurement test on cyclophosphamide-induced overactive bladder model rat". Owing to these effects, the above compound is useful as a remedy for ovaractive bladder.
Inventor(s): Takasu; Toshiyuki (Tsukuba, JP), Sato; Shuichi (Tsukuba, JP), Ukai; Masashi (Tsukuba, JP), Maruyama; Tatsuya (Tsukuba, JP)
Assignee: Astellas Pharma Inc. (Tokyo, JP)
Application Number:10/534,290
Patent Claims: 1. A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or a salt thereof as an active ingredient, wherein the subject is not suffering from diabetes.

2. The method according to claim 1, wherein the overactive bladder is a result of benign prostatic hyperplasia.

3. The method according to claim 1, wherein the subject has urinary urgency.

4. The method according to claim 1, wherein the subject has urinary urge incontinence.

5. The method according to claim 1, wherein the subject has pollakiuria.

6. A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide, in its free base form, as an active ingredient, wherein the subject is not suffering from diabetes.

7. The method according to claim 6, wherein the overactive bladder is a result of benign prostatic hyperplasia.

8. The method according to claim 6, wherein the subject has urinary urgency.

9. The method according to claim 6, wherein the subject has urinary urge incontinence.

10. The method according to claim 6, wherein the subject has pollakiuria.

11. The method according to claim 1, wherein the subject is human.

12. The method according to claim 6, wherein the subject is human.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc